AstraZeneca and Daiichi Sankyo Secure FDA Approval for Datroway in Frontline TNBC

The FDA has granted approval to Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for immunotherapy [2.1.1]. Developed by AstraZeneca and Daiichi Sankyo, this marks the first frontline TROP2-directed antibody-drug conjugate approved beyond chemotherapy for this patient population.